Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

STAT-C: a full revolution or just a step forward?

Milazzo L, Antinori S.

Lancet. 2010 Aug 28;376(9742):662-3. doi: 10.1016/S0140-6736(10)61056-2. Epub 2010 Aug 6. No abstract available.

PMID:
20692692
2.

[Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications].

Lange CM, Sarrazin C, Zeuzem S.

Pharm Unserer Zeit. 2011 Jan;40(1):60-7. doi: 10.1002/pauz.201100401. Review. German. No abstract available.

PMID:
21194084
3.

HCV protease inhibitors bring new options for patients.

Traynor K.

Am J Health Syst Pharm. 2011 Aug 1;68(15):1372, 1374, 1379. doi: 10.2146/news110051. No abstract available.

PMID:
21785015
4.

A major advance in treating hepatitis C.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2011 Dec;23(10):6. No abstract available.

PMID:
22216468
5.

[Hepatitis C update: what has changed? What can we expect in the near future?].

Geier A.

MMW Fortschr Med. 2013 Nov 7;155(19):59-62. Review. German. No abstract available.

PMID:
24475674
6.

[New times for the treatment of chronic hepatitis C].

Gerstoft J, Fomsgaard A.

Ugeskr Laeger. 2012 Mar 19;174(12):795. Danish. No abstract available.

PMID:
22433552
7.

[New antiviral agents against hepatitis C in clinical trials. Hope for a cure--but resistance problems must be overcomed].

Lennerstrand J, Bondeson K, Bergqvist A, Blomberg J, Oberg B.

Lakartidningen. 2009 Nov 25-Dec 1;106(48):3254-6, 3258, 3260. Review. Swedish. No abstract available.

PMID:
20101837
8.

Update on the use of direct-acting antiviral agents for the treatment of chronic hepatitis C virus infection.

Fernández-Yunquera A, Rincón D, Salcedo M, Bañares R.

Rev Esp Quimioter. 2013 Sep;26(3):189-92. Review. No abstract available.

9.

New developments in HCV therapy.

Kronenberger B, Zeuzem S.

J Viral Hepat. 2012 Jan;19 Suppl 1:48-51. doi: 10.1111/j.1365-2893.2011.01526.x.

PMID:
22233414
10.

Infectious diseases. First specific drugs raise hopes for hepatitis C.

Enserink M.

Science. 2011 Apr 8;332(6026):159-60. doi: 10.1126/science.332.6026.159. No abstract available.

PMID:
21474720
11.

[A new era in therapy of hepatitis C: "the therapy can now be individualized" (interview by Dr. med. Dirk Einecke)].

Manns M.

MMW Fortschr Med. 2011 Jul 21;153(29-31):17. German. No abstract available.

PMID:
21830729
12.

[Boceprevir (Victrelis), oral administration].

[No authors listed]

J Pharm Belg. 2012 Jun;(2):37-9. Review. French. No abstract available.

PMID:
22978014
13.

Triple therapy for hepatitis C.

Giordano C.

JAAPA. 2012 Feb;25(2):59-60. No abstract available.

PMID:
22416558
14.

[Therapy of hepatitis C: new inhibitors as hammers against HCV].

Bublak R.

MMW Fortschr Med. 2013 Jun 13;155 Suppl 1:10-1. German. No abstract available.

PMID:
23961643
15.

Viral hepatitis C in 2014--the beginning of the end?

Prelipcean CC, Gogălniceanu P, Mihai C.

Rev Med Chir Soc Med Nat Iasi. 2014 Apr-Jun;118(2):272-8. No abstract available.

PMID:
25076687
16.

The FDA, bridging data, and hepatitis C.

Fried MW, Jensen DM.

Hepatology. 2013 Mar;57(3):875-7. doi: 10.1002/hep.26177. No abstract available.

PMID:
23456679
17.

Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.

Butt AA, Kanwal F.

Clin Infect Dis. 2012 Jan 1;54(1):96-104. doi: 10.1093/cid/cir774. Epub 2011 Dec 7. Review.

PMID:
22156853
18.

[Victrelis and Incivek against hepatitis C: some promising options].

Sabourin G.

Perspect Infirm. 2012 Jan-Feb;9(1):58-9. French. No abstract available.

PMID:
22295460
19.

Drugs in development for viral hepatitis: care and caution.

Pockros PJ.

Drugs. 2011 Feb 12;71(3):263-71. doi: 10.2165/11587090-000000000-00000. No abstract available.

PMID:
21319865
20.

Supplemental Content

Support Center